Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

SIMPLE SUMMARY: Neoadjuvant chemotherapy (NACT) is the standard treatment for early-stage triple-negative breast cancer (TNBC). Achieving pathological complete response (pCR) is considered an essential prognostic factor with favorable long-term outcomes. The administration of NACT regimens with plat...

Descripción completa

Detalles Bibliográficos
Autores principales: Holanek, Milos, Selingerova, Iveta, Bilek, Ondrej, Kazda, Tomas, Fabian, Pavel, Foretova, Lenka, Zvarikova, Maria, Obermannova, Radka, Kolouskova, Ivana, Coufal, Oldrich, Petrakova, Katarina, Svoboda, Marek, Poprach, Alexandr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036281/
https://www.ncbi.nlm.nih.gov/pubmed/33808149
http://dx.doi.org/10.3390/cancers13071586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036281/
https://www.ncbi.nlm.nih.gov/pubmed/33808149
http://dx.doi.org/10.3390/cancers13071586

Ejemplares similares